1,2 Abdulaziz AlGharras

1 Department of Radiology, King Fahad Specialist Hospital, Buraidah, 2Department of Radiology, Unaizah College of Medicine and Medical Sciences, Al Qassim University


To evaluate the technical and clinical success rates and safety of Gelfoam uterine artery embolization (UAE) for symptomatic uterine fibroids.

Material(s) and Method(s):

Retrospective cohort study done at King Fahad Hospital in Buraydah, Qassim, Saudi Arabia. Patients who underwent UAE between September 1, 2020 and December 31, 2021 for treatment of symptomatic uterine fibroids were included in this analysis. The exclusion criteria were the patients in who refuse to undergo UAE or received other embolization particles.  Patient data was collected between the time of their initial procedure and December 31, 2021. Data extraction and chart review for baseline characteristics, procedural data, complications, secondary procedures if required, post procedural follow-up in 6 months. MRI results at 0 and 6 months. Statistical analysis was performed using SPSS (IBM, New York).


Ten patients included in this analysis. Mean age 42 years. Median follow-up for the UAE was 6 months. UAE success rate was 100% in both sides. Patients’ symptoms markedly improved within few days after the procedure. Single non clinically significant small hematoma at the access site encountered required overnight observation prior discharge with no requirement for transfusion. No major post procedure complication seen. Post procedure MRI at 6 months, showed 90% success rate in term of ischemia toward fibroid tissue, one patient had incomplete devasculization of the multiple fibroids required repeat treatment.


UAE with Gelfoam in the treatment of patients with symptomatic uterine fibroids is cheaper, safe and effective as compared to standard PVA or embolization particles.